(NASDAQ:EGRX) by 25.4% during the first quarter, Holdings Channel reports. 384009 shares were traded on Eagle Pharmaceuticals Inc's last session. Finally, Norges Bank acquired a new stake in Eagle Pharmaceuticals during the fourth quarter valued at approximately $5,634,000. It looks like analysts are feeling bearish about the stock with overall sell-side analysts calling it a Buy. Putnam Investments LLC raised its position in shares of Eagle Pharmaceuticals by 16.4% in the fourth quarter. Comerica Bank now owns 8,445 shares of the specialty pharmaceutical company's stock worth $585,000 after buying an additional 415 shares during the last quarter. FMR LLC acquired a new position in shares of Eagle Pharmaceuticals during the fourth quarter valued at about $7,300,000. Mason Street Advisors LLC now owns 1,895 shares of the specialty pharmaceutical company's stock valued at $157,000 after buying an additional 175 shares during the last quarter. Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has risen 79.40% since July 26, 2016 and is uptrending. Municipal Employees Retirement System of MI boosted its position in Eagle Pharmaceuticals by 6.7% in the second quarter. Municipal Employees Retirement System of MI now owns 1,910 shares of the specialty pharmaceutical company's stock valued at $151,000 after buying an additional 120 shares during the last quarter. Eagle Pharmaceuticals has a 52 week low of $42.33 and a 52 week high of $97.15. (NASDAQ:EGRX) opened at 70.04 on Wednesday. The firm has a market capitalization of $816.45 million, a PE ratio of 8.39 and a beta of 1.48. The company's 50-day moving average is $75.97 and its 200-day moving average is $77.70. The firm's revenue for the quarter was up 159.5% compared to the same quarter past year. The specialty pharmaceutical company reported $1.42 earnings per share for the quarter, missing analysts' consensus estimates of $1.44 by $0.02. During the same quarter in the previous year, the company earned ($0.06) EPS. BNP Paribas Arbitrage SA now owns 1,548 shares of the specialty pharmaceutical company's stock valued at $128,000 after buying an additional 202 shares during the last quarter. Equities research analysts predict that Eagle Pharmaceuticals, Inc. will post $3.66 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This article was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of USA and worldwide trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/07/27/wellington-management-group-llp-acquires-shares-of-4897-eagle-pharmaceuticals-inc-egrx.html.
EGRX has been the subject of several other reports. Royal Bank Of Canada set a $86.00 target price on Eagle Pharmaceuticals and gave the company a "buy" rating in a research report on Monday, April 24th. Zacks Investment Research raised shares of Eagle Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Tuesday, May 2nd. Mizuho lowered their price target on shares of Eagle Pharmaceuticals from $66.00 to $57.00 and set an "underperform" rating on the stock in a research report on Thursday, May 25th.
Juventus, Buffon: "Diversi senza Bonucci. Dybala? Le parole contano" 1425 27-07
Se Bonucci ha litigato con qualcuno? Averlo salutato o no dipende dal tipo di vicinanza che hai e da quanto usi i social. Partiamo con un sistema definito e la società ha operato per avere alternative più congeniali al modulo.
12/09/2015 - Eagle Pharmaceuticals Inc had its "buy" rating reiterated by analysts at William Blair. Analysts have placed a $91.75 price target on Eagle Pharmaceuticals, Inc., suggesting a 26.03% gain from recent close.
In related news, CFO Pete A. Meyers purchased 350 shares of the business's stock in a transaction that occurred on Monday, June 12th. Following the completion of the transaction, the chief financial officer now directly owns 350 shares of the company's stock, valued at $25,021.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last three months, insiders bought 805 shares of company stock worth $61,790. During the trading on 07/26/2017, Company's stock ranged from $71.880 to $52.215.